FdaApplication
ANDA 210771
Identifiers
- fda_app_no: ANDA210771
Properties
| Property | Value |
|---|---|
| applicant_name | PRINSTON PHARMACEUTICAL INC |
| application_type | ANDA |
| approval_date | 2023-03-20 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LEVOMILNACIPRAN HYDROCHLORIDE | LEVOMILNACIPRAN HYDROCHLORIDE | EQ 20MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| LEVOMILNACIPRAN HYDROCHLORIDE | LEVOMILNACIPRAN HYDROCHLORIDE | EQ 120MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| LEVOMILNACIPRAN HYDROCHLORIDE | LEVOMILNACIPRAN HYDROCHLORIDE | EQ 80MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| LEVOMILNACIPRAN HYDROCHLORIDE | LEVOMILNACIPRAN HYDROCHLORIDE | EQ 40MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
4 products